MX2022014868A - Inhibidores de cxcr-2 para tratar trastornos. - Google Patents

Inhibidores de cxcr-2 para tratar trastornos.

Info

Publication number
MX2022014868A
MX2022014868A MX2022014868A MX2022014868A MX2022014868A MX 2022014868 A MX2022014868 A MX 2022014868A MX 2022014868 A MX2022014868 A MX 2022014868A MX 2022014868 A MX2022014868 A MX 2022014868A MX 2022014868 A MX2022014868 A MX 2022014868A
Authority
MX
Mexico
Prior art keywords
cxcr
inhibitors
activity
treating disorders
diseases
Prior art date
Application number
MX2022014868A
Other languages
English (en)
Inventor
Payal Nanavati
Johan Hoegstedt
Jesse Hall
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/702,693 external-priority patent/US20180221312A1/en
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of MX2022014868A publication Critical patent/MX2022014868A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

N-(6-(((2R,3S)-3,4-dihidroxi butan-2-il)oxi)-2-((4-fluoro bencil)tio)pirimidin-4-il)-3-metilazetidina-1-sulfonamida (compuesto 4), un conocido modulador de quimiocinas, en combinación con colchicina es útil en el tratamiento de enfermedades/afecciones en las cuales la modulación de la actividad de los receptores de quimiocinas, la actividad de la interleuquina-1 (IL-1) y/o la actividad de la mieloperoxidasa (MPO) es beneficiosa. En particular, en la presente invención, se proveen composiciones y métodos para el tratamiento y la prevención de dichas enfermedades/afecciones. (ver Fórmula) Compuesto 4.
MX2022014868A 2017-09-12 2020-03-11 Inhibidores de cxcr-2 para tratar trastornos. MX2022014868A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15/702,693 US20180221312A1 (en) 2016-03-11 2017-09-12 Cxcr-2 inhibitors for treating disorders

Publications (1)

Publication Number Publication Date
MX2022014868A true MX2022014868A (es) 2022-12-15

Family

ID=65723077

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002754A MX2020002754A (es) 2017-09-12 2018-09-12 Inhibidores de cxcr-2 para tratar trastornos.
MX2022014868A MX2022014868A (es) 2017-09-12 2020-03-11 Inhibidores de cxcr-2 para tratar trastornos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020002754A MX2020002754A (es) 2017-09-12 2018-09-12 Inhibidores de cxcr-2 para tratar trastornos.

Country Status (11)

Country Link
EP (1) EP3681861A4 (es)
JP (1) JP2020533332A (es)
CN (1) CN111356675A (es)
AR (1) AR112801A1 (es)
AU (1) AU2018334152A1 (es)
BR (1) BR112020004697A2 (es)
CA (1) CA3075305A1 (es)
CO (1) CO2020003061A2 (es)
MX (2) MX2020002754A (es)
TW (1) TW201919599A (es)
WO (1) WO2019055509A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018068393A2 (pt) 2016-03-11 2019-01-15 Ardea Biosciences Inc inibidores de cxcr-2 para o tratamento de distúrbios de artropatia por cristais
US20220404373A1 (en) * 2019-09-25 2022-12-22 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and treating uveitis
WO2021089715A1 (en) * 2019-11-06 2021-05-14 Murray And Poole Enterprises, Ltd. Use of colchicine in the treatment and prevention of lung cancer
EP4058456A1 (en) * 2019-11-13 2022-09-21 RAPT Therapeutics, Inc. Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof
TW202210068A (zh) * 2020-06-05 2022-03-16 美商雅力思提雅治療公司 用於治療家族性地中海型發熱病的cxcr-2抑制劑
TWI774059B (zh) * 2020-09-14 2022-08-11 國立陽明大學 Ｃｘｃｌ５中和抗體用於製備預防或治療周邊動脈阻塞疾病的藥物的用途
TW202227081A (zh) * 2020-09-15 2022-07-16 美商雅力思提雅治療公司 用於治療掌蹠膿疱症之組合物及方法
JP2023543248A (ja) * 2020-09-24 2023-10-13 ▲広▼州▲輯▼因医▲療▼科技有限公司 ヒト造血幹細胞移植効率を向上させるための化合物の使用
CN115385865B (zh) * 2022-06-29 2023-06-16 深圳大学 一种具有cxcr2抑制活性的小分子抑制剂及其制备方法与应用
CN117503740A (zh) * 2023-11-09 2024-02-06 复旦大学 一种bach1抑制剂及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ548499A (en) * 2004-01-30 2010-06-25 Schering Corp Crystalline polymorphs of a CXC-chemokine receptor ligand
US8298533B2 (en) * 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
CA2841859C (en) * 2011-07-12 2021-03-09 Astrazeneca Ab N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio)pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator
BR112018068393A2 (pt) * 2016-03-11 2019-01-15 Ardea Biosciences Inc inibidores de cxcr-2 para o tratamento de distúrbios de artropatia por cristais

Also Published As

Publication number Publication date
AU2018334152A1 (en) 2020-04-23
JP2020533332A (ja) 2020-11-19
EP3681861A1 (en) 2020-07-22
CO2020003061A2 (es) 2020-06-19
MX2020002754A (es) 2020-07-20
AR112801A1 (es) 2019-12-11
CN111356675A (zh) 2020-06-30
WO2019055509A1 (en) 2019-03-21
CA3075305A1 (en) 2019-03-21
TW201919599A (zh) 2019-06-01
BR112020004697A2 (pt) 2020-10-27
EP3681861A4 (en) 2021-06-09

Similar Documents

Publication Publication Date Title
MX2022014868A (es) Inhibidores de cxcr-2 para tratar trastornos.
MX2018010946A (es) Inhibidores de cxcr-2 para tratamiento de trastornos de artropatia por cristales.
PH12020552060A1 (en) Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
MX2022016434A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
MX2019010949A (es) Moduladores de somatostatina y usos de los mismos.
MX2023000056A (es) Compuestos tricíclicos de urea como inhibidores de la variante v617f de la cinasa de janus 2 (jak2 v617f).
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
MX2020007586A (es) Proceso de fabricacion de moduladores de somatostatina.
MX2020013085A (es) Antagonistas del receptor de subtipo 2 de melanocortina (mc2r) y usos de los mismos.
GEP20247596B (en) Crystalline forms and salt forms of a kinase inhibitor
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
MX2022002597A (es) Métodos de tratamiento de la epilepsia usando los métodos.
PH12020551179A1 (en) Methods for treating mitochondrial disorder
MX2021011488A (es) Compuestos y usos de estos.
PE20210109A1 (es) Moduladores de la expresion de irf4
MX2023008589A (es) Compuestos moduladores de gcn2 y usos de los mismos.
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2022011576A (es) Moduladores de nlrp3.
MX2019014771A (es) Inhibidores de la proteína -1 de adhesión vascular para uso en la prevención o tratamiento de migraña.
MX2021008941A (es) Moduladores gpr35.
EA202192047A1 (ru) Соединения и их применение
MX2021008903A (es) Compuestos y usos de los mismos.
WO2022251212A3 (en) Uses of a somatostatin modulator for the treatment of disease